We propose verifying the functional benefit of early high-dose corticosteroids in a global, multi-racial prospective study including patients with inaugural MS-ON, AQP4-IgG+ON, and MOG-IgG+ON. The gene discussed is MOG; the disease is myeloid sarcoma.